These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 5072392)

  • 21. Aromatic amino acid decarboxylase inhibitors.
    Porter CC
    Fed Proc; 1971; 30(3):871-6. PubMed ID: 5575298
    [No Abstract]   [Full Text] [Related]  

  • 22. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM; Dubuc R; Barbeau A
    Lancet; 1972 Aug; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract]   [Full Text] [Related]  

  • 23. [The therapeutic effect of L-dopa].
    Groneberg P; Struppler A
    Naturwissenschaften; 1972 Nov; 59(11):492-6. PubMed ID: 4657650
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A; Mars H; Botez MI; Joubert M
    Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
    Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
    Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
    [No Abstract]   [Full Text] [Related]  

  • 26. Levodopa and related drugs.
    Med Lett Drugs Ther; 1973 Mar; 15(5):21-3. PubMed ID: 4697470
    [No Abstract]   [Full Text] [Related]  

  • 27. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 29. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
    Kuzuya F; Wakita T; Kawahara H
    Nihon Naika Gakkai Zasshi; 1972 Sep; 61(9):1131-5. PubMed ID: 4674039
    [No Abstract]   [Full Text] [Related]  

  • 30. Levadopa and psoriasis.
    Barbeau A; Giroux JM
    Lancet; 1972 Jan; 1(7743):204-5. PubMed ID: 4109575
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug-induced changes in brain dopamine and their relation to parkinsonism.
    Vogt M
    Sci Basis Med Annu Rev; 1970; ():276-91. PubMed ID: 4319923
    [No Abstract]   [Full Text] [Related]  

  • 32. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P
    Acta Neurol Scand Suppl; 1972; 51():111-3. PubMed ID: 4514333
    [No Abstract]   [Full Text] [Related]  

  • 35. Pyridoxine antagonism of levodopa in parkinsonism.
    Leon AS; Spiegel HE; Thomas G; Abrams WB
    JAMA; 1971 Dec; 218(13):1924-7. PubMed ID: 5171069
    [No Abstract]   [Full Text] [Related]  

  • 36. Dopamine: stimulation-induced release from central neurons.
    Ng KY; Chase TN; Colburn RW; Kopin IJ
    Science; 1971 Apr; 172(3982):487-9. PubMed ID: 5550505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa.
    Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R; Kvan L; Presthus J; Thoresen GB
    Acta Neurol Scand Suppl; 1972; 51():121-2. PubMed ID: 4514336
    [No Abstract]   [Full Text] [Related]  

  • 39. L-Dopa and Parkinsonism.
    Calne DB; Sandler M
    Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK
    Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.